373 related articles for article (PubMed ID: 28888037)
1. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.
Baena-Del Valle JA; Zheng Q; Esopi DM; Rubenstein M; Hubbard GK; Moncaliano MC; Hruszkewycz A; Vaghasia A; Yegnasubramanian S; Wheelan SJ; Meeker AK; Heaphy CM; Graham MK; De Marzo AM
J Pathol; 2018 Jan; 244(1):11-24. PubMed ID: 28888037
[TBL] [Abstract][Full Text] [Related]
2. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
3. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
4. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue.
Paradis V; Dargère D; Laurendeau I; Benoît G; Vidaud M; Jardin A; Bedossa P
J Pathol; 1999 Oct; 189(2):213-8. PubMed ID: 10547577
[TBL] [Abstract][Full Text] [Related]
5. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc.
Pu H; Zheng Q; Li H; Wu M; An J; Gui X; Li T; Lu D
Oncotarget; 2015 Dec; 6(38):40775-98. PubMed ID: 26513297
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
[TBL] [Abstract][Full Text] [Related]
7. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein.
Zhang X; Lee C; Ng PY; Rubin M; Shabsigh A; Buttyan R
Prostate; 2000 Jun; 43(4):278-85. PubMed ID: 10861747
[TBL] [Abstract][Full Text] [Related]
8. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.
Koh CM; Khattar E; Leow SC; Liu CY; Muller J; Ang WX; Li Y; Franzoso G; Li S; Guccione E; Tergaonkar V
J Clin Invest; 2015 May; 125(5):2109-22. PubMed ID: 25893605
[TBL] [Abstract][Full Text] [Related]
9. Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer.
Bettendorf O; Heine B; Kneif S; Eltze E; Semjonow A; Herbst H; Stein H; Böcker W; Poremba C
Prostate; 2003 May; 55(2):99-104. PubMed ID: 12661034
[TBL] [Abstract][Full Text] [Related]
10. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
11. The telomerase RNA component Terc is required for the tumour-promoting effects of Tert overexpression.
Cayuela ML; Flores JM; Blasco MA
EMBO Rep; 2005 Mar; 6(3):268-74. PubMed ID: 15731767
[TBL] [Abstract][Full Text] [Related]
12. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
13. Widespread telomere instability in prostatic lesions.
Tu L; Huda N; Grimes BR; Slee RB; Bates AM; Cheng L; Gilley D
Mol Carcinog; 2016 May; 55(5):842-52. PubMed ID: 25917938
[TBL] [Abstract][Full Text] [Related]
14. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of myc and telomerase interactions in vivo.
Flores I; Evan G; Blasco MA
Mol Cell Biol; 2006 Aug; 26(16):6130-8. PubMed ID: 16880523
[TBL] [Abstract][Full Text] [Related]
16. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
Gurel B; Iwata T; Koh CM; Jenkins RB; Lan F; Van Dang C; Hicks JL; Morgan J; Cornish TC; Sutcliffe S; Isaacs WB; Luo J; De Marzo AM
Mod Pathol; 2008 Sep; 21(9):1156-67. PubMed ID: 18567993
[TBL] [Abstract][Full Text] [Related]
17. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
18. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study.
Kamradt J; Drosse C; Kalkbrenner S; Rohde V; Lensch R; Lehmann J; Fixemer T; Bonkhoff H; Stoeckle M; Wullich B
Lab Invest; 2003 May; 83(5):623-33. PubMed ID: 12746472
[TBL] [Abstract][Full Text] [Related]
20. Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.
Zhang Y; Calado R; Rao M; Hong JA; Meeker AK; Dumitriu B; Atay S; McCormick PJ; Garfield SH; Wangsa D; Padilla-Nash HM; Burkett S; Zhang M; Kunst TF; Peterson NR; Xi S; Inchauste S; Altorki NK; Casson AG; Beer DG; Harris CC; Ried T; Young NS; Schrump DS
PLoS One; 2014; 9(7):e101010. PubMed ID: 24983628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
